Creative Planning acquired a new stake in Abeona Therapeutics Inc (NASDAQ:ABEO) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 68,374 shares of the biopharmaceutical company’s stock, valued at approximately $875,000. Creative Planning owned approximately 0.14% of Abeona Therapeutics at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Parkside Advisors LLC bought a new position in shares of Abeona Therapeutics in the 3rd quarter valued at about $160,000. United Services Automobile Association bought a new position in shares of Abeona Therapeutics in the 2nd quarter valued at about $162,000. Northern Trust Corp grew its holdings in shares of Abeona Therapeutics by 28.2% in the 2nd quarter. Northern Trust Corp now owns 390,342 shares of the biopharmaceutical company’s stock valued at $6,246,000 after acquiring an additional 85,908 shares in the last quarter. FMR LLC grew its holdings in shares of Abeona Therapeutics by 47.7% in the 2nd quarter. FMR LLC now owns 7,094,307 shares of the biopharmaceutical company’s stock valued at $113,509,000 after acquiring an additional 2,291,016 shares in the last quarter. Finally, California Public Employees Retirement System grew its holdings in shares of Abeona Therapeutics by 120.3% in the 2nd quarter. California Public Employees Retirement System now owns 55,508 shares of the biopharmaceutical company’s stock valued at $888,000 after acquiring an additional 30,316 shares in the last quarter. Institutional investors own 76.38% of the company’s stock.
Several equities analysts have recently weighed in on ABEO shares. Cantor Fitzgerald set a $36.00 price objective on Abeona Therapeutics and gave the company a “buy” rating in a report on Monday, October 1st. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 24th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Abeona Therapeutics in a report on Thursday, September 13th. ValuEngine downgraded shares of Abeona Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 11th. Finally, TheStreet downgraded shares of Abeona Therapeutics from a “c-” rating to a “d+” rating in a research note on Wednesday, August 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company. Abeona Therapeutics has a consensus rating of “Buy” and a consensus target price of $26.80.
Shares of NASDAQ:ABEO opened at $9.23 on Monday. Abeona Therapeutics Inc has a 52-week low of $8.52 and a 52-week high of $22.00.
Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.06). Abeona Therapeutics had a negative net margin of 881.74% and a negative return on equity of 23.02%. The firm had revenue of $0.82 million during the quarter, compared to analyst estimates of $1.81 million. As a group, sell-side analysts expect that Abeona Therapeutics Inc will post -0.88 EPS for the current fiscal year.
Abeona Therapeutics Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Read More: Google Finance Portfolio Workaround
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.